Celldex Therapeutics, Inc. — Director's Dealing 2008

Feb 28, 2008

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: AVANT IMMUNOTHERAPEUTICS INC (AVAN)
CIK: 0000744218
Period of Report: 2007-01-31

Reporting Person: Paluck Thomas S (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, par value $0.001 per share	4300114	Direct
Common Stock, par value $0.001 per share	130000	Indirect
Common Stock, par value $0.001 per share	3202232	Indirect

Footnotes

F1: As of December 31, 2007 (the "Reporting Date"), Thomas S. Paluck held 1,000,000 shares of common stock, par value $0.001 per share (the "Shares"), of AVANT Immunotherapeutics, Inc. (the "company"), which includes 230,000 Shares held in the name of Dorothy Paluck, Mr. Paluck's wife.

F2: In addition, as of the Reporting Date, TSP Capital Management Group, LLC ("TSP") managed one or more private investment accounts on behalf of various clients (the "Managed Accounts"), which owned in the aggregate 6,632,346 Shares. Mr. Paluck is the sole principal of TSP. In addition, Mr. Paluck possesses sole power to direct the disposition of the securities held by the Managed Accounts. Thus, as of the Reporting Date, for the purposes of Reg. Section 240.13d-3, Mr. Paluck may be deemed to beneficially own 7,632,346 Shares or 10.3% of the Shares issued and outstanding as of the Reporting Date. The reporting person hereby expressly disclaims membership in a "group" under the Securities Exchange Act of 1934 with respect to the securities reported herein, and this Form 3 shall not be deemed to be an admission that the reporting person is a member of such a group.

F3: The reporting person hereby expressly disclaims beneficial ownership of the securities reported herein, other than to the extent of his pecuniary interest therein, and this Form 3 shall not be deemed to be an admission that the reporting person is the beneficial owner of the securities reported herein for purposes of the Securities Exchange Act of 1934 or for any other purpose.